Aier Eye Hospital Group could become a multi-bagger due to its high capital compounding rates. Despite higher stock prices, strong fundamentals warrant further research.
Despite the recent decline in share price, long-term investors have seen a 15% return each year over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering.
Aier Eye Hospital Group's high P/E ratio, despite weaker growth predictions, pose risks for investors. The high P/E amidst lower growth forecasts suggest a potential for declining value in investments.
Aier Eye Hospital Group shows promising trends, hinting at potential multi-bagger status. High ROCE and continuous capital reinvestment suggest a bright future, but further research is advised due to strong performance.
$滬深300(000300.SH)$$iShares MSCI China A ETF(CNYA.US)$ UOB KH report. MSCI China now trades at an undemanding 12-month forward PE of 10.2x, or a 37.0% discount to Emerging Asia. This steep discount is unwarranted and they expect valuation to normalise in 2H23, backed by additional policy support. However, a significant rerating is only possible if credit growth accelerates; hence, their index target is at 74 points for now, implying 12.0x target PE. They prefer exposure to automobiles, co...
Core point 1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream 2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
愛爾眼科股票討論區
UOBKH: Healthcare – China (Overweight)
UOBKH: Healthcare – China (Overweight) - Alpha Edge Investing
$藥明生物(02269.HK)$$藥明康德(02359.HK)$$信達生物(01801.HK)$$啓明醫療-B(02500.HK)$$復宏漢霖(02696.HK)$$愛爾眼科(300015.SZ)$$邁瑞醫療(300760.SZ)$
UOBKH: Alpha Picks – July Conviction Calls (Greater China)
UOBKH: Alpha Picks – July Conviction Calls (Greater China) - Alpha Edge Investing
$碧桂園服務(06098.HK)$$理想汽車-W(02015.HK)$$雙環傳動(002472.SZ)$$領展房產基金(00823.HK)$$長城汽車(02333.HK)$$愛爾眼科(300015.SZ)$$安踏體育(02020.HK)$$比亞迪股份(01211.HK)$$寧德時代(300750.SZ)$$中國海外發展(00688.HK)$$中遠海運港口(01199.HK)$$匯川技術(300124.SZ)$$貝殼-W(02423.HK)$$快手-W(01024.HK)$$貴州茅臺(600519.SH)$$騰訊控股(00700.HK)$
UOB KH report.
MSCI China now trades at an undemanding 12-month forward PE of 10.2x, or a 37.0% discount to Emerging Asia. This steep discount is unwarranted and they expect valuation to normalise in 2H23, backed by additional policy support. However, a significant rerating is only possible if credit growth accelerates; hence, their index target is at 74 points for now, implying 12.0x target PE. They prefer exposure to automobiles, co...
專欄Expert Meeting Minutes | Seven Development Trends of the China Medical Aesthetics Industry
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
暫無評論